Dabigatran Etexilate Versus Warfarin in the Treatment of Venous Thromboembolism

被引：0

作者：

Schulman, Sam ^{[1
]}

Eriksson, Henry ^{[2
]}

Goldhaber, Samuel Z. ^{[3
]}

Kakkar, Ajay K. ^{[4
]}

Kearon, Clive ^{[5
]}

Mismetti, Patrick ^{[6
]}

Schellong, Sebastian M. ^{[7
]}

Baanstra, David ^{[8
]}

Schnee, Janet ^{[9
]}

机构：

[1] McMaster Univ, Dept Med, Hamilton, ON, Canada

[2] Sahlgrens Univ Hosp, Gothenburg, Sweden

[3] Brigham & Womens Hosp, Boston, MA 02115 USA

[4] Barts & London Queen Marys Sch Med & Dent, Thrombosis Res Inst, London, England

[5] McMaster Univ Clin, Henderson Hosp, Hamilton, ON, Canada

[6] Bellevue Hosp, St Etienne, France

[7] Municipal Hosp Friedrichstadt, Med Div 2, Dresden, Germany

[8] Boehringer Ingelheim GmbH & Co KG, Clin Res, Alkmaar, Netherlands

[9] Boehringer Ingelheim GmbH & Co KG, Ridgefield, CT USA

来源：

BLOOD | 2009年 / 114卷 / 22期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：3 / 3

页数：1

共 50 条

[31] Drug evaluation: Dabigatran etexilate, a thrombin inhibitor for the prevention of venous thromboembolism and stroke
Ieko, Masahiro
CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2007, 8 (09) : 758 - 768
[32] Dabigatran Etexilate or Warfarin in the Treatment of Acute Venous Thromboembolism in Western European Patients: A Pooled Analysis of RE-COVER® and RE-COVER II™
Schellong, Sebastian
Eriksson, Henry
Goldhaber, Samuel Z.
Feuring, Martin
Hantel, Stefan
Kreuzer, Joerg
Schulman, Sam
Kakkar, Ajay K.
BLOOD, 2015, 126 (23)
[33] Dabigatran etexilate: A new oral direct thrombin inhibitor for the management of venous thromboembolism
Eriksson, Bengt
THROMBOSIS AND HAEMOSTASIS, 2008, 100 (06) : A11 - A14
[34] Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients with atrial fibrillation
Dzeshka, Mikhail S.
Lip, Gregory Y. H.
EXPERT OPINION ON DRUG SAFETY, 2015, 14 (01) : 45 - 62
[35] Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data
Ma, Terry K. W.
Yan, Bryan P.
Lam, Yat-Yin
PHARMACOLOGY & THERAPEUTICS, 2011, 129 (02) : 185 - 194
[36] Insights from the dabigatran versus warfarin trial in patients with venous thromboembolism (the RE-COVER trial)
Prandoni, Paolo
Taher, Ali
EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (06) : 1035 - 1037
[37] Dabigatran vs. warfarin in venous thromboembolism: a meta-analysis
Sipahi, I.
Cuhadaroglu, C.
EUROPEAN HEART JOURNAL, 2015, 36 : 308 - 308
[38] Dabigatran Etexilate: Pivotal Trials for Venous Thromboembolism Prophylaxis After Hip or Knee Arthroplasty
Eriksson, Bengt I.
Friedman, Richard J.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2009, 15 : 25S - 31S
[39] A COST-UTILITY ANALYSIS OF PROPHYLACTIC THERAPY FOR VENOUS THROMBOEMBOLISM WITH DABIGATRAN ETEXILATE OR ENOXAPARIN
Burbano-Levy, X.
Herran, S.
Sanchez, G.
Mieth, K.
Alfonso-Cristancho, R.
VALUE IN HEALTH, 2011, 14 (07) : A535 - A535
[40] Prevention and Treatment of Venous Thromboembolic Events: Focus on Dabigatran Etexilate
Cheng, Judy W. M.
CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2011, 3 : 205 - 220

← 1 2 3 4 5 →